Developer Of First US OTC COVID-19 Antigen Test Plans 'Digital Diagnostics For Multitude Of Infectious Diseases'

06 May 2021

The developer of the OTC at-home antigen test — the first of its kind to get an emergency use authorization from the FDA – received more than $200m from the US government to manufacture in the US. So what’s next for Ellume? In this Q&A, the Australian company’s CEO, Sean Parson, explains.

Earlier this year the Biden administration made a big bet on small Australian test maker Ellume Ltd. by giving it $231m to build a plant in the US to mass produce its OTC at-home antigen tests.

The test received an emergency use authorization (EUA) from the Food and Drug Administration in December and is touted as...